Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis
- 1 October 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 43 (10), 1331-1340
- https://doi.org/10.1097/pas.0000000000001298
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized oncology, but are associated with immune-related adverse events. Clinically, pneumonitis is a well-recognized complication, but its histopathologic features are poorly understood. Institutional archives were searched for patients having ICI therapy and subsequent lung tissue sampling. After excluding infectious cases, 9 patients (5 women, median: 59 y) were identified with clinically suspected ICI-related pneumonitis. Clinical history, imaging, and pathology slides were reviewed. Patients received pembrolizumab (6 cases), nivolumab (1), ipilimumab followed by pembrolizumab (1), or pembrolizumab followed by nivolumab (1); the latter experienced pneumonitis with both agents. Treatment duration ranged from 1 to 33 cycles (median: 8). Three patients received concurrent chemotherapy and 1 received radiation; the remainder received ICI monotherapy. Symptoms were nonspecific; 2 patients were asymptomatic. Thoracic imaging showed bilateral ground glass or nodular opacities in all cases, often with pleural effusion. Histologically, organizing pneumonia was seen in 7 patients, all with subclinical or mild disease, admixed with vague non-necrotizing airspace granulomas in 3 cases; all 6 patients with follow-up did well. One patient had acute fibrinous pneumonitis and 1 had diffuse alveolar damage; both died. All 9 cases showed foamy macrophages and pneumocyte vacuolization; 6 had rare eosinophils. ICI-related pneumonitis presents as bilateral ground-glass opacities or nodules, and usually manifests as organizing pneumonia histopathologically, often with vague non-necrotizing airspace granulomas. Foamy macrophages and pneumocyte vacuolization are characteristic and rare eosinophils are often seen. Less commonly, acute fibrinous pneumonitis or diffuse alveolar damage can occur, which may be fatal.Keywords
This publication has 30 references indexed in Scilit:
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2017
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnnals Of Oncology, 2016
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case ReportsPLOS ONE, 2016
- Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy studyJournal for ImmunoTherapy of Cancer, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of MelanomaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- Pathologic aspects of bronchiolitis obliterans organizing pneumoniaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1992
- Hyperplasia of Type II Pneumocytes in Acute Lung Injury: Cytologic Findings of Sequential Bronchoalveolar LavageAmerican Journal of Clinical Pathology, 1992
- Bronchiolitis Obliterans and Usual Interstitial PneumoniaThe American Journal of Surgical Pathology, 1986